Prof. Thomas Powles (Barts Cancer Institute, UK) presented the results of the phase 3, multicentre, multinational, randomised, open-label, parallel-arm JAVELIN Bladder 100 study in patients with locally advanced or metastatic urothelial cancer whose disease did not progress after completion of first-line, platinum-containing chemotherapy. The study met its primary endpoint by showing significantly longer overall survival with avelumab first-line maintenance versus control, both in the overall population and the PD-L1+ population .
First-line, platinum-based chemotherapy for advance bladder cancer is characterised by frequent resistance, and PD-L1/PD-1 inhibitors, such as avelumab, are standard second-line treatment for patients with disease progression; however, only a minority of patients obtain a durable clinical benefit . The JAVELIN Bladder 100 trial investigated avelumab as first-line...
please login to read the entire article:
You need to register to read the entire article, please do so now.
« Adjuvant osimertinib in NSCLC: practice changing ADAURA trial Next Article
COVID-19 and Cancer Consortium Registry: initial results »
Table of Contents: ASCO 2020
COVID-19 & Telemedicine
Breast & Ovarian Cancer
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.